← Back to Search

Elranatamab Access for Multiple Myeloma (MagnetisMM15 Trial)

Phase 4
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a minimum of 90 days after the last dose of study drug
Awards & highlights

MagnetisMM15 Trial Summary

This trial gives MM patients continued access to elranatamab, a drug that has helped them. It's sponsored by Pfizer.

Who is the study for?
This trial is for people with Multiple Myeloma who are benefiting from Elranatamab in ongoing Pfizer studies. They must agree to follow reproductive safety measures and cannot join if they've left the original study or have conditions that increase risk or suicidal thoughts recently.Check my eligibility
What is being tested?
The study provides continued access to Elranatamab, a medication under investigation, for participants who were part of previous trials (Parent Studies) and are still seeing positive effects from the treatment.See study design
What are the potential side effects?
While specific side effects of Elranatamab aren't listed here, similar treatments often cause immune reactions, fatigue, nausea, bone marrow suppression which can lead to infections or bleeding problems.

MagnetisMM15 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a minimum of 90 days after the last dose of study drug
This trial's timeline: 3 weeks for screening, Varies for treatment, and a minimum of 90 days after the last dose of study drug for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation
Incidence of serious adverse events (SAEs)

MagnetisMM15 Trial Design

1Treatment groups
Experimental Treatment
Group I: ElranatamabExperimental Treatment1 Intervention
Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Elranatamab
2022
N/A
~510

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,583 Previous Clinical Trials
14,635,461 Total Patients Enrolled
36 Trials studying Multiple Myeloma
9,858 Patients Enrolled for Multiple Myeloma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,488 Previous Clinical Trials
11,812,412 Total Patients Enrolled
25 Trials studying Multiple Myeloma
5,128 Patients Enrolled for Multiple Myeloma
~48 spots leftby Feb 2031
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top